LX1001 explained
LX1001 is an experimental gene therapy for Alzheimer's disease associated with mutations to the APOE4 gene. The gene therapy is delivered via adeno-associated virus injected into the spinal canal and is intended to increase the expression of APOE2.[1] [2] [3]
Notes and References
- Ayyubova . Gunel . APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease . CNS & Neurological Disorders Drug Targets . March 2024 . 23 . 3 . 342–352 . 10.2174/1871527322666230303114425. 36872358 . 257363252 .
- Thomas . Uduak . Antibodies Take Center Stage in Alzheimer's: Antibody-based treatments have transformed oncology, and they could do the same for neurodegenerative disorders like Alzheimer's disease . Genetic Engineering & Biotechnology News . 1 November 2023 . 43 . 11 . 30–32, 34 . 10.1089/gen.43.11.11. 265134072 .
- Cummings . Jeffrey L. . Osse . Amanda M. Leisgang . Kinney . Jefferson W. . Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification . Drugs . October 2023 . 83 . 15 . 1387–1408 . 10.1007/s40265-023-01938-w. 37728864 . 10582128 . free .